Roche moved to expand Foundation Medicine’s oncology monitoring capabilities by agreeing to acquire SAGA Diagnostics in a deal valued at up to $595 million, including milestones. Foundation Medicine plans to integrate SAGA’s Pathlight MRD platform, which detects structural variants using a combination of whole-genome sequencing and digital PCR. Pathlight is already covered by Medicare for recurrence monitoring in early-stage breast cancer, and the companies plan to extend access internationally. Roche also outlined plans for decentralized MRD workflows by combining Pathlight with Roche’s AXELIOS sequencing and Digital LightCycler PCR technologies. The acquisition underscores how MRD is consolidating into scalable, platform-based diagnostics rather than bespoke assays—an important direction for companion diagnostics and longitudinal trial endpoints.